220 related articles for article (PubMed ID: 20504100)
1. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
3. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.
Katsikis I; Karkanaki A; Misichronis G; Delkos D; Kandaraki EA; Panidis D
Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):181-5. PubMed ID: 21353371
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
6. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
8. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
[TBL] [Abstract][Full Text] [Related]
9. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
Liou TH; Yang JH; Hsieh CH; Lee CY; Hsu CS; Hsu MI
Fertil Steril; 2009 Dec; 92(6):1960-5. PubMed ID: 18980763
[TBL] [Abstract][Full Text] [Related]
11. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinaemia in polycystic ovary syndrome.
Lunde O
Ann Chir Gynaecol; 1981; 70(4):197-201. PubMed ID: 6797343
[TBL] [Abstract][Full Text] [Related]
13. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome.
Cho LW; Jayagopal V; Kilpatrick ES; Holding S; Atkin SL
Ann Clin Biochem; 2006 May; 43(Pt 3):217-9. PubMed ID: 16704758
[TBL] [Abstract][Full Text] [Related]
14. Glucose intolerance in Japanese patients with polycystic ovary syndrome.
Kurioka H; Takahashi K; Miyazaki K
Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071
[TBL] [Abstract][Full Text] [Related]
15. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia.
Banaszewska B; Spaczyński RZ; Pelesz M; Pawelczyk L
Rocz Akad Med Bialymst; 2003; 48():131-4. PubMed ID: 14737959
[TBL] [Abstract][Full Text] [Related]
16. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
17. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
18. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
20. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
